June 27, 2022
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Doris Stacey Gama
| Re: | Qualigen Therapeutics, Inc. – Request for Acceleration | |
| Registration Statement on Form S-3 | ||
| File No. 333- 265691 |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 265691) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on Wednesday, June 29, 2022, or as soon thereafter as practicable.
The Registrant hereby authorizes Wendy Grasso, Esq. of Reed Smith LLP, attorney for the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso, Esq. at (212) 549-0216.
| QUALIGEN THERAPEUTICS, INC. | ||
| By: | /s/ Michael Poirier | |
| Michael Poirier | ||
| Chairman & Chief Executive Officer | ||
2042 Corte del Nogal, Carlsbad, CA 92011 Tel 877.709.2169 Fax 760.918.9165 www.qualigeninc.com